Background
==========

Diastolic heart failure (DHF) is a clinical syndrome characterized by the symptoms and signs of heart failure, a preserved ejection fraction and abnormal diastolic function \[[@b1-medscimonit-18-1-cr25]\]. The percentage of patients with DHF in epidemiological studies ranges from 40--71% (mean 56%), but in hospital-based cohort studies it is slightly lower, ranging from 24--55% (mean 41%) \[[@b2-medscimonit-18-1-cr25]\]. Elderliness, hypertension with left ventricular (LV) hypertrophy, pathologies such as diabetes, obesity, coronary artery disease, new onset atrial fibrillation, and others are commonly associated with DHF \[[@b2-medscimonit-18-1-cr25]--[@b4-medscimonit-18-1-cr25]\].

Cardiotrophin-1 (CT-1) is a member of the interleukin (IL)-6 cytokine family that shares the transmembrane signaling protein, glycoprotein (gp) 130, as a receptor \[[@b4-medscimonit-18-1-cr25]\]. CT-1 mRNA is expressed in adult human heart, skeletal muscle, ovary, colon, prostate and testis and in fetal kidney and lung \[[@b5-medscimonit-18-1-cr25]\]. CT-1 has hypertrophic and cytoprotective actions on the cardiac myocytes and may play an important role in other organ systems \[[@b6-medscimonit-18-1-cr25],[@b7-medscimonit-18-1-cr25]\]. The plasma concentration of CT-1 is increased in various cardiovascular diseases such as congestive heart failure, hypertension, valvular heart disease, acute coronary syndrome, and cardiomyopathies \[[@b8-medscimonit-18-1-cr25]--[@b18-medscimonit-18-1-cr25]\].

Although, the prognostic importance of CT-1 in various cardiovascular diseases, including congestive heart failure, is well-known, there is limited data about CT-1 in patients with DHF. The purpose of the present study was to determine if CT-1 levels are significantly different in DHF patients compared to controls and to investigate the relationship between CT-1 and echocardiographic parameters.

Material and Methods
====================

Study population
----------------

Fifty-seven consecutive patients (mean age 57±8 years, 24 (42%) males) diagnosed with DHF in our clinic and 33 controls (mean age 55±7 years, 12 (36%) males) were included in the study. DHF was diagnosed when symptoms (dyspnea not associated with any other cause) and signs (rale or peripheral edema) of heart failure were observed along with a preserved LV ejection fraction (LVEF) (≥50%) and evidence of diastolic dysfunction. The control group was formed from volunteer subjects admitted to our clinic who did not have heart failure symptoms and signs and who had a preserved LVEF. In order to exclude other causes of dyspnea, all patients underwent physical and laboratory examinations, including serum hemoglobin and thyroid hormones, chest radiogram and spirometry. Patients with systolic heart failure, moderate or severe valvular stenosis or regurgitation, congenital heart disease, atrial fibrillation, chronic obstructive pulmonary disease, malignancy, and other extracellular fluid-increasing diseases, such as hypothyroidism and liver cirrhosis, were excluded from the study.

The present study was a single center study. All examinations were performed by the cardiology clinic of our hospital. The investigation conforms to the principles outlined in the Declaration of Helsinki. All subjects gave their written informed consent prior to inclusion in the study. The study protocol was approved by the ethics committee at our institution.

Echocardiographic measurements
------------------------------

All of the study participants underwent echocardiographic evaluation (2.5 mHz transducer, Philips EnVisor C, Bothell, Washington, USA). Standardized projections and measurements were performed for the evaluation of cardiac anatomy, ventricular function and valve competence. LVEF was measured using Simpson's method \[[@b19-medscimonit-18-1-cr25]\]. Left ventricular mass was calculated by the formula described by Devereux et al. and LV mass index was obtained by dividing the LV mass by the body surface area \[[@b20-medscimonit-18-1-cr25]\]. The following conventional mitral inflow pulse wave Doppler parameters were measured: peak velocity of early diastolic filling (E), late filling (A), and deceleration time (DT) of the E-wave velocity and isovolumetric relaxation time (IVRT). These parameters were obtained from the apical four-chamber view with a 1 to 3 mm sample volume placed between the mitral leaflet tips during diastole. Pulmonary venous flow parameters were also measured: peak systolic velocity (Ps), peak anterograde diastolic velocity (Pd) and the Ps/Pd ratio. These parameters were obtained from the apical four-chamber view with a 2 to 3 mm sample volume placed 1 cm into the pulmonary vein. Tissue Doppler parameters were measured: peak systolic mitral annular velocity (Sm) and early diastolic mitral annular velocity (Em) and late diastolic mitral velocity (Am). These parameters were obtained from the apical four-chamber view with a 2 to 5 mm sample volume placed 1 cm within the septal and lateral insertions of the mitral leaflets. The mean of 3 or more measurements was used for analysis of the Doppler data. The ratio of mitral peak velocity of early diastolic filling to early diastolic mitral annular velocity (E/Em) was calculated for the lateral and septal annulus and the mean of the lateral and septal E/Em were also determined. As previously described, the formula (1.24×(E/Em)+1.9) was used to estimate pulmonary capillary wedge pressure (PCWP) \[[@b21-medscimonit-18-1-cr25]\]. Patients with mean E/Em ≤8 or a change in E/A ratio with the Valsalva maneuver of \<0.5 were excluded from the study. Diastolic dysfunction was defined as Em \<Am if Em was less than 10 cm/sec in lateral mitral annulus or less than 8 cm/sec in septal mitral annulus \[[@b22-medscimonit-18-1-cr25]\].

Biochemical measurements
------------------------

Blood samples were obtained during admission for routine chemistry, including CT-1 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) following an overnight fast. CT-1 values were measured with a sandwich enzyme immunoassay method (Organon Teknika Microwell System Reader 230 S, Germany) in our hospital laboratory. NT-proBNP analyses were made by the electrochemiluminescence immunoassay method (Cobas 6000 analyzer, ROCHE Diagnostics GmbH, Mannheim, Germany). The Cockcroft-Gault formula was used to calculate creatinine clearance \[[@b14-medscimonit-18-1-cr25]\].

Statistical analysis
--------------------

According to Kolmogorov-Smirnov normality test, 2 independent sample T tests were used to compare the normally distributed independent variables between the 2 groups, and Mann-Whitney U Test was used to compare the non-normally distributed independent variables between the 2 groups. Normally distributed continuous data were expressed as mean ± standard deviation (SD); non-normally distributed continuous variables were presented as median and interquartile range (IQR) \[quartile l to quartile 3\]. Chi-square test was used for comparing the categorical data. Categorical data were expressed as count and percentages. Spearman's correlation test was used for correlation between variables. Linear regression analyses were used to determine the effect of age, creatinine clearance, systolic blood pressure, left atrium diameter, and LV mass index on log CT-1 and log NT-proBNP. *P* values below 0.05 were considered statistically significant. Statistical analysis was performed by using commercial software (IBM SPSS Statistics 19, SPSS inc., an IBM Co., Somers, NY)

Results
=======

There were no significant differences between the patient and control groups with regard to age, sex, hypertension, diabetes, CAD, smoking, medications, body mass index, fasting blood glucose, thyroid status, lipid profile, creatinine clearance, serum creatinine and hemoglobin levels ([Table 1](#t1-medscimonit-18-1-cr25){ref-type="table"}). The patient group had a higher LV posterior wall thickness and a larger left atrial size, but differences in LVEF, chamber sizes, and mass index remained insignificant ([Tables 1](#t1-medscimonit-18-1-cr25){ref-type="table"} and [2](#t2-medscimonit-18-1-cr25){ref-type="table"}). Arterial blood pressures were also not different between the 2 groups. CT-1 and NT-proBNP were significantly higher in the patient group (CT-1: 11.30 \[8.09--16.51\] fmol/ml *vs.* 17.5 \[8.95--28.74\] fmol/ml, *P*=0.017; NT-proBNP: 64 \[27.5--95\] pg/ml *vs.* 82 \[55.5--241\] pg/ml, *P*=0.009) ([Table 1](#t1-medscimonit-18-1-cr25){ref-type="table"}). The mitral E, lateral, septal and mean E/Em and the PCWP estimated from each of the E/Em measurements were all significantly higher, whereas Ps/Pd, lateral and septal Em and lateral and septal Em/Am were significantly lower in the patient group ([Table 2](#t2-medscimonit-18-1-cr25){ref-type="table"}).

CT-1 positively correlated with NT-proBNP (*P*=0.001, r=0.349), mean E/Em (*P*=0.003, r=0.307), and estimated mean PCWP (*P*=0.001, r=0.308) ([Figure 1](#f1-medscimonit-18-1-cr25){ref-type="fig"}). According to bivariate linear regression analyses, log CT-1 was predicted by left atrium diameter and log NT-proBNP was predicted by age, creatinine clearance, and left atrium diameter ([Table 3](#t3-medscimonit-18-1-cr25){ref-type="table"}). In multiple linear regression analysis, log CT-1 and log NT-proBNP were predicted only by left atrium diameter ([Table 4](#t4-medscimonit-18-1-cr25){ref-type="table"}).

Discussion
==========

The data of this study shows that the CT-1 is elevated in DHF patients and is associated with NT-proBNP and estimated LV filling pressures in DHF patients.

CT-1 is a cytokine that causes hypertrophic and cytoprotective effects on the cardiac myocytes \[[@b5-medscimonit-18-1-cr25]\]. The CT-1 protein expression is constitutive not only in the heart, but also in the pulmonary, renal, gastrointestinal, cerebral, and muscular tissues. CT-1 is also expressed by vascular endothelial cells and adipocytes \[[@b6-medscimonit-18-1-cr25]\]. Cardiac myocytes and cardiac fibroblasts may produce CT-1 in situations of biomechanical stress and under exposure to humoral factors such as angiotensin II and norepineprine \[[@b23-medscimonit-18-1-cr25]--[@b25-medscimonit-18-1-cr25]\]. Ventricular stretch caused by pressure or volume overload is thought to be the major stimulus of myocardial CT-1 release \[[@b26-medscimonit-18-1-cr25]\].

Previous studies have found that CT-1 promotes myocardial structural changes, later participating in the progression of LV remodeling, which results in LV failure in various diseases such as hypertensive heart disease, coronary artery disease, aortic stenosis, and dilated cardiomyopathy \[[@b27-medscimonit-18-1-cr25]\]. Both BNP and CT-1 have a beneficial effect not only on the myocardium but also on hemodynamic variables \[[@b28-medscimonit-18-1-cr25]\].

Therefore, ongoing stimulation of BNP and CT-1 caused by ventricular stretch and circulating cytokines, promote structural remodeling and may become maladaptive with the progression of heart failure \[[@b17-medscimonit-18-1-cr25]\]. CT-1 levels correlate with the severity of the heart failure and has been shown to be an independent predictor of mortality in chronic heart failure \[[@b9-medscimonit-18-1-cr25],[@b27-medscimonit-18-1-cr25]\]. Plasma CT-1 has high diagnostic efficacy for heart failure (at concentration of 68 fmol/ml, sensitivity and specificity were 95% and 82.5%, respectively) \[[@b29-medscimonit-18-1-cr25]\]. Talwar et al found that plasma CT-1 levels measured shortly after an acute myocardial infarction serve as a strong independent predictor of LV systolic dysfunction \[[@b16-medscimonit-18-1-cr25]\].

In another study, Talwar et al. found that changes in CT-1 levels may reflect early changes in ventricular physiology that occur in the early part of the heart failure process before they can be detected echocardiographically \[[@b12-medscimonit-18-1-cr25]\]. It was also found that CT-1 is significantly increased in patients with moderate to severe mitral regurgitation despite having normal LV systolic function and no hypertrophy. They were unable to demonstrate a similar increase in subjects with tricuspid or aortic regurgitation. In our study, we showed CT-1 elevation in a group of DHF patients with normal LV systolic function and no significant hypertrophy, but having more dilated left atrium than controls. Considering these results, it may be speculated that left atrial wall stretch is a more important and earlier stimulation for CT-1 secretion rather than ventricular wall stretch. It has already been shown that CT-1 mRNA was detected in both atria and ventricles \[[@b5-medscimonit-18-1-cr25],[@b30-medscimonit-18-1-cr25]\].

In a series of studies performed by Lopez et al, they concluded that CT-1 is a more sensitive and specific biomarker than NT-pro BNP for detection of the inappropriateness of LV mass and LV dysfunction in hypertension, and NT-pro BNP remains a useful diagnostic tool for hypertensive heart disease only when LV systolic dysfunction is present \[[@b11-medscimonit-18-1-cr25],[@b31-medscimonit-18-1-cr25]\]. It was also shown that elevated CT-1 levels represent an earlier stage of the same neurohumoral cascade that results in elevated plasma BNP \[[@b12-medscimonit-18-1-cr25]\]. CT-1 increases BNP secretion from cardiomyocytes *in vitro*\[[@b23-medscimonit-18-1-cr25]\]. In our study, both CT-1 and NT-pro BNP were found to be more elevated in DHF patients than in control subjects, and there was a positive correlation between CT-1 and NT-pro BNP. Our findings are consistent with the previous studies.

Previous studies show that elevated NT-proBNP values is diagnostic for DHF and associated with elevated LV filling pressures \[[@b32-medscimonit-18-1-cr25],[@b33-medscimonit-18-1-cr25]\]. It has been found that there is a strong correlation between NT-proBNP and E/Em, and a threshold of 269.1 pg/mL of NT-proBNP predicted an E/Em \>15 with 90% sensitivity and 73% specificity in DHF \[[@b34-medscimonit-18-1-cr25]\]. The positive correlation between elevated CT-1 and NT-proBNP, E/Em and PCWP in our study implies that pressure overload represented as increases in LV filling pressures could be the main underlying mechanism for CT-1 secretion in patients with DHF.

There is limited data about CT-1 in patients with DHF. A series of studies performed by Lopez et al concluded that CT-1 is associated with systolic and diastolic dysfunction in hypertensive patients \[[@b11-medscimonit-18-1-cr25]\]. In the other study they found that the ratio of peak velocity of early diastolic filling to peak velocity of late filling of mitral inflow (E/A) is the only parameter that differed in the hypertensive group, while DT and IVRT remained unchanged \[[@b31-medscimonit-18-1-cr25]\]. Significant association was found between normalization of CT-1 and regression of LV hypertrophy and increment of E/A \[[@b10-medscimonit-18-1-cr25]\]. In their studies they only used conventional Doppler parameters in order to evaluate diastolic function, and E/A was the only parameter found to be different from the control group. In our study we evaluated diastolic functions with conventional and tissue Doppler parameters. CT-1 was significantly higher in the DHF group and also correlated with these parameters.

Chronic CT-1 treatment resulted in the development of insulin resistance as judged by a decrease in insulin-stimulated glucose uptake \[[@b35-medscimonit-18-1-cr25]\]. We found high glucose levels in DHF patients, but this difference was insignificant, probably due to small sample size.

There are potential limitations of this study. First, the sample size was relatively small. Second, despite the evidences that E/Em is an effective noninvasive predictor of LV filling pressures, we did not measure LV pressures directly. Third, both of our study groups were obese. It was already known that adipose tissue can be recognized as a source of CT-1, which could account for the high circulating levels of CT-1 in patients with metabolic syndrome \[[@b36-medscimonit-18-1-cr25]\]. A study with lean subjects may reveal the true association between CT-1 and DHF. Finally, CT-1 mRNA is expressed in other organs, and potential additional sources of circulating CT-1 cannot be excluded in patients with DHF \[[@b5-medscimonit-18-1-cr25]\].

Conclusions
===========

CT-1 values were found to be increased in patients with DHF. This increase was associated with NT-proBNP and estimated LV filling pressures in DHF patients. Our results suggest that diastolic dysfunction and subsequent pressure increase at the left side of the heart may be responsible for CT-1 increase in DHF patients. However, further studies are required to elucidate the underlying mechanism for the CT-1 increase in these patients.
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###### 

Baseline characteristics and laboratory findings of patient and control groups.

                                         Control (n=33)          Patient (n=57)         *P* value
  -------------------------------------- ----------------------- ---------------------- -----------------------------------------------------------------
  Age (years)                            55±7                    57±8                   0.205
  Gender (Male)                          12 (36)                 24 (42)                0.592
  Hypertension                           19 (58)                 43 (74)                0.115
  Diabetes                               8 (24)                  16 (28)                0.692
  Coronary artery disease                6 (18)                  20 (35)                0.088
  Smoking                                7 (21)                  11 (19)                0.827
  RAS blockers                           11 (33)                 30 (53)                0.076
  β-blockers                             7 (21)                  20 (35)                0.166
  Calcium channel blockers               7 (21)                  9 (16)                 0.517
  Statins                                6 (18)                  15 (26)                0.379
  Acetyl salicylic acid                  11 (33)                 24 (42)                0.411
  Body mass index (kg/m^2^)              30.3±4.3                31.3±4.2               0.281
  Systolic blood pressure (mmHg)         132±23                  139±21                 0.173
  Diastolic blood pressure (mmHg)        80 \[70--90\]           85 \[80--90\]          0.530
  Glucose (mg/dL)                        99 \[92--110\]          105 \[93--127\]        0.132
  Thyroid stimulating hormone (μIU/mL)   1.30 \[0.85--1.70\]     1.20 \[0.8--1.85\]     0.834
  Creatinine (mg/dL)                     0.7 \[0.6--0.9\]        0.8 \[0.6--0.9\]       0.990
  Ceatinine clearance (mL/min/1.73 m2)   114±28                  115±36                 0.906
  Cholesterol (mg/dL)                    196±42                  196±42                 0.961
  Triglyceride (mg/dL)                   161±89                  153±61                 0.614
  LDL-cholesterol (mg/dL)                127±36                  125±40                 0.979
  HDL-cholesterol (mg/dL)                45±11                   46±13                  0.493
  Hemoglobin (gr/dL)                     13.7±1.6                13.4±1.6               0.475
  CT-1 (fmol/mL)                         11.30 \[8.09--16.51\]   17.5 \[8.95--28.74\]   **0.002**[\*](#tfn2-medscimonit-18-1-cr25){ref-type="table-fn"}
  NT-proBNP (pg/mL)                      64 \[27.5--95\]         82 \[55.5--241\]       **0.007**[\*](#tfn2-medscimonit-18-1-cr25){ref-type="table-fn"}

RAS -- Renin-angiotensin system; LDL -- Low-density lipoprotein; HDL -- High-density lipoprotein; CT-1 -- Cardiotrophin-1; NT-proBNP -- N terminal pro B-type natriuretic peptide. Data are shown as n (%), mean ± SD, median \[interquartile range\].

calculated by log transformed data.

###### 

Echocardiographic parameters of patient and control groups.

                                          Control (n=33)                                                      Patient (n=57)                                                      *P* value
  --------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- -------------
  LVEF (%)                                69 \[64--73\]                                                       72 \[65--75\]                                                       0.380
  LVEDD (mm)                              46.6±6.4                                                            46.1±5.0                                                            0.633
  LVESD (mm)                              29.7±4.7                                                            29.9±4.2                                                            0.866
  IVSD (mm)                               11 \[[@b10-medscimonit-18-1-cr25]--[@b12-medscimonit-18-1-cr25]\]   12 \[[@b10-medscimonit-18-1-cr25]--[@b13-medscimonit-18-1-cr25]\]   0.317
  PWD (mm)                                9 \[[@b9-medscimonit-18-1-cr25]--[@b11-medscimonit-18-1-cr25]\]     11 \[[@b10-medscimonit-18-1-cr25]--[@b12-medscimonit-18-1-cr25]\]   **0.003**
  Left atrium diameter (mm)               34.7±4.1                                                            38.1±5.3                                                            **0.002**
  Left ventricular mass index (gr/m^2^)   96.0±19.0                                                           99.5±20.4                                                           0.424
  Ps/Pd                                   1.29±0.34                                                           1.07±0.30                                                           **0.002**
  E (cm/sec)                              62.27±14.69                                                         75.67±18.85                                                         **0.001**
  A (cm/sec)                              75.48±21.95                                                         83.07±22.30                                                         0.121
  E/A                                     0.79 \[0.65--1.04\]                                                 0.85 \[0.76--1.00\]                                                 0.273
  DT (msec)                               224±46                                                              218±45                                                              0.519
  IVRT (msec)                             88±17                                                               96±25                                                               0.355
  *Lateral*                                                                                                                                                                       
  Sm (cm/sec)                             9.22±2.03                                                           8.92±2.17                                                           0.524
  Em (cm/sec)                             10.69±1.87                                                          8.69±2.00                                                           **\<0.001**
  Am (cm/sec)                             11.88±2.35                                                          11.74±3.19                                                          0.828
  Em/Am                                   0.87 \[0.74--1.02\]                                                 0.71 \[0.63--0.86\]                                                 **0.006**
  E/Em                                    5.70 \[5.05--6.83\]                                                 8.47 \[6.96--10.47\]                                                **\<0.001**
  PCWP (mmHg)                             9.00 \[8.00--10.50\]                                                12.00 \[10.50--15.00\]                                              **\<0.001**
  *Septal*                                                                                                                                                                        
  Sm (cm/sec)                             8.18±1.36                                                           7.63±1.60                                                           0.100
  Em (cm/sec)                             8.91±1.22                                                           6.65±1.58                                                           **\<0.001**
  Am (cm/sec)                             10.78±1.57                                                          10.34±2.52                                                          0.367
  Em/Am                                   0.82 \[0.70--0.91\]                                                 0.63 \[0.57--0.72\]                                                 **\<0.001**
  E/Em                                    7.05±1.67                                                           11.90±3.84                                                          **\<0.001**
  PCWP (mmHg)                             10.00 \[9.00--12.00\]                                               16.00 \[13.00--18.50\]                                              **\<0.001**
  E/Em mean                               6.40±1.48                                                           10.30±3.48                                                          **\<0.001**
  PCWP mean (mmHg)                        10.00 \[9.00--11.00\]                                               14.00 \[12.00--16.00\]                                              **\<0.001**

LVEF -- left ventricular ejection fraction; LVEDD -- left ventricular end-diastolic dimension; LVESD -- left ventricular end-systolic dimension; IVSD -- interventricular septal dimension; PWD -- posterior wall dimension; Ps/Pd -- ratio of peak systolic velocity and peak anterograd diastolic velocity of pulmonary venous flow; E -- peak velocity of early diastolic filling; A -- peak velocity of late filling; DT -- deceleration time of the E-wave velocity; IVRT -- isovolumetric relaxation time; Sm -- peak systolic mitral annular velocity; Em -- early diastolic mitral annular velocity; Am -- late diastolic mitral annular velocity; E/Em -- early mitral inflow velocity to early diastolic mitral annular velocity ratio; PCWP -- pulmonary capillary wedge pressure. Data are shown as mean ± SD, median \[interquartile range\].

###### 

Bivariate linear regression models for log CT-1 and log NT-proBNP.

  Dependent variable            Independent variables   β coefficient   Standard error   *P* value
  ----------------------------- ----------------------- --------------- ---------------- -------------
  Log CT-1                      Age                     0.010           0.007            0.131
  Creatinine clearance          −0.002                  0.002           0.336            
  Systolic blood pressure       0.001                   0.003           0.732            
  Left atrium diameter          0.024                   0.010           **0.025**        
  Left ventricular mass index   0.002                   0.003           0.426            
  Log NT-proBNP                 Age                     0.026           0.007            **\<0.001**
  Creatinine clearance          −0.005                  0.002           **0.002**        
  Systolic blood pressure       0.001                   0.003           0.786            
  Left atrium diameter          0.030                   0.011           **0.007**        
  Left ventricular mass index   0.005                   0.003           0.080            

CT-1 -- Cardiotrophin-1; NT-proBNP -- N terminal pro B-type natriuretic peptide.

###### 

Multiple linear regression models for log CT-1 and log NT-proBNP.

  Dependent variable            Independent variables   β coefficient   Standard error   P value
  ----------------------------- ----------------------- --------------- ---------------- ---------
  Log CT-1                      Constant                −0.060          0.730            0.934
  Age                           0.005                   0.008           0.533            
  Creatinine clearance          −0.001                  0.002           0.604            
  Systolic blood pressure       0.001                   0.003           0.564            
  Left atrium diameter          0.023                   0.011           **0.049**        
  Left ventricular mass index   0.000                   0.003           0.957            
  Log NT-proBNP                 Constant                0.315           0.709            0.658
  Age                           0.015                   0.008           0.066            
  Creatinine clearance          −0.003                  0.002           0.083            
  Systolic blood pressure       0.001                   0.002           0.721            
  Left atrium diameter          0.023                   0.011           **0.033**        
  Left ventricular mass index   0.002                   0.003           0.510            

CT-1 -- Cardiotrophin-1; NT-proBNP -- N terminal pro B-type natriuretic peptide.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
